Company intelligence / Profile preview

Holoclara

California, United Statesholoclara.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Holoclara has initiated a first-in-human Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of its orally available worm-derived therapeutic candidate HC002 in healthy adults. Preclinical studies have shown efficacy in mouse models of asthma, type 1 diabetes, and IBD. The company’s approach leverages decades of data on the immunomodulatory effects of nematode secretions to address allergic and autoimmune disorders.

Therapeutic areas: GastroenterologyImmunology
Modalities: small molecules (worm-derived immunomodulatory compounds)
Industry: Biotech

Drug pipeline

1 asset

HC002

Partnerships

Investors include BOLD Capital Partners and Kairos Ventures; no major pharma partnerships publicly announced as of May/June 2025.

Beyond the preview

Go deeper on Holoclara.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Holoclara.

Explore the full profile